These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 37436507)

  • 1. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
    Cheng S; Hu G; Jin Z; Wang Z; Xue H
    Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Lyu T; Yao H; Wang J; Song L; Tong X; Zou Y
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101819. PubMed ID: 34619365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
    Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
    Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
    Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
    Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection.
    Liu F; Guo X; Dong W; Zhang W; Wei S; Zhang S; Zhu X; Zhou W; Zhang J; Liu H
    Int J Biol Sci; 2020; 16(16):3210-3220. PubMed ID: 33162826
    [No Abstract]   [Full Text] [Related]  

  • 8. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 9. Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization.
    Li J; Zhang Y; Ye H; Hu L; Li X; Li Y; Yu P; Wu B; Lv P; Li Z
    Acad Radiol; 2023 Sep; 30 Suppl 1():S40-S52. PubMed ID: 37316369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial.
    Zhou TY; Tao GF; Zhou GH; Zhang YL; Zhu TY; Chen SQ; Wang HL; Wang BQ; Jing L; Chen F
    Int J Surg; 2024 Sep; 110(9):5527-5537. PubMed ID: 38775550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomics nomogram for the prediction of microvascular invasion of HCC and patients' benefit from postoperative adjuvant TACE: a multi-center study.
    Zhang K; Zhang L; Li WC; Xie SS; Cui YZ; Lin LY; Shen ZW; Zhang HM; Xia S; Ye ZX; He K; Shen W
    Eur Radiol; 2023 Dec; 33(12):8936-8947. PubMed ID: 37368104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads.
    Cheng S; Yu X; Liu S; Jin Z; Xue H; Wang Z; Xie P
    Cancer Manag Res; 2021; 13():9367-9377. PubMed ID: 34992462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
    Xi Z; Ye Y; Yang Y; He Y; Song Z; Ma Q; Zeng H; Shao G
    Abdom Radiol (NY); 2024 Jul; 49(7):2387-2400. PubMed ID: 39030402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT.
    Ma X; Wei J; Gu D; Zhu Y; Feng B; Liang M; Wang S; Zhao X; Tian J
    Eur Radiol; 2019 Jul; 29(7):3595-3605. PubMed ID: 30770969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
    Li L; Kan X; Zhao Y; Liang B; Ye T; Yang L; Zheng C
    Int J Med Sci; 2021; 18(11):2276-2284. PubMed ID: 33967603
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study.
    Zhao GS; Liu S; Liu Y; Li C; Wang RY; Bian J; Zhang YW; Zhou J; Lin YJ; Wu J
    Expert Rev Gastroenterol Hepatol; 2022 Jul; 16(7):673-680. PubMed ID: 35709813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score.
    Liu K; Zheng X; Dai J; Hou C; Lu D; Zhao B; Yin S; Wang G; Cao Q; Jiang B; Gao S; Huang X; Xie J; Zhang Y; Li S; Zhang A; Yang W; Wang S; Tan Y; Shi W; Lv W; Wu X
    Acad Radiol; 2024 Oct; 31(10):4034-4044. PubMed ID: 38508935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
    Chen J; Lai L; Luo J; Wang H; Li M; Huang M
    BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
    Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
    Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.